UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the quarterly period ended January 31, 2018
	For the quarterly period ended April 30, 2018
or
¨	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the transition period from _______________ to _______________

Commission File Number 333-214643

SUNSET ISLAND GROUP, INC.

(Exact name of registrant as specified in its charter)

Colorado		8247-~~08844860~~3278534
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

555 N. El Camino Real #A418, San Clemente, CA		92672
20420 Spence Road, Salinas, CA		93908
(Address of principal executive offices)		(Zip Code)

(424) 239-6230

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	None	None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ¨ YES x NO

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). x YES ¨ NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	x	Smaller reporting company	x
		Emerging growth company	x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) ¨ YES x NO

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court. ¨ YES ¨ NO

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

5,386,771 shares of common stock as of ~~July~~October 19, 2019

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION		3
Item 1.	Financial Statements		3
Item 2.	Management'’s Discussion and Analysis of Financial Condition or Plan of Operation		1620
Item 3.	Quantitative and Qualitative Disclosures About Market Risk		1926
Item 4.	Controls and Procedures		1926
PART II - OTHER INFORMATION			21
Item 1.	Legal Proceedings		2127
Item 1A.	Risk Factors		2127
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		2127
Item 3.	Defaults Upon Senior Securities		2127
Item 4.	Mine Safety Disclosures		2127
Item 5.	Other Information		2127
Item 6.	Exhibits		2128
SIGNATURES			2229

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

Sunset Island Group, Inc.

Condensed Consolidated Balance ~~Sheet~~Sheets

	January 31,			October 31,
	April 30,			October 31,
	2018			2017
Assets
Current Assets
Cash and cash equivalents	$	2289,~~740~~050		$	24,656
Total Current Assets		2289,~~740~~050			24,656
Deposit		14,000			14,000
Total Assets	$	16303,~~740~~050		$	38,656
Liabilities and Stockholders’ Deficit
Liabilities and Stockholders' Deficit
Current Liabilities
Accounts payable and accrued liabilities	$	1815,~~240~~642		$	25,817
Accrued interest - related party		497			-
Accrued interest		24,913			-
Dividend payable		46,029			46,029
Accrued interest - related party		3,109			-
Due to related party		2,885			2,885
Dividend payable		97,416			46,029
Convertible note, net of unamortized discount of $33,123		136,877			-
Due to related party		3,438			2,885
Convertible notes, net of unamortized discount of $829,855		285,145			-
Current portion of notes payable - related party		157,200			-
Total Current Liabilities		361,728			74,731
Derivative liabilities		928,872			-
Total Current Liabilities		1,515,735			74,731
Notes payable - related party		272,200			330,200
Total Liabilities		~~633~~1,~~928~~787,935			404,931
Commitments and Contingencies (note 7)
Commitments and Contingencies (note 9)
Stockholders’ Equity (Deficit)
Stockholders' Deficit
Preferred stock, $0.0001 par value, 15,000,000 shares authorized;
Preferred stock, $0.0001 par value, 15,000,000 shares authorized; Series A Convertible Preferred Stock, 4,600,000 shares designated, 4,600,000 shares issued and outstanding		460			460
Series A Convertible Preferred Stock, 4,600,000 shares designated, 4,600,000 shares issued and outstanding		460			460
Series B Preferred Stock, 8,000,000 shares designated, no shares issued and outstanding		-			-
Series C Convertible Preferred Stock, 500,000 shares designated, no shares issued and outstanding		-			-
Common Stock, par value $0.0001, 27,000,000 shares authorized, 5,371,771 and 4,871,771 shares issued and outstanding, respectively		537			487
Common Stock, par value $0.0001, 27,000,000 shares authorized, 5,386,771 and 4,871,771 shares issued and outstanding, respectively		539			487
Additional paid in capital		~~463~~494,~~403~~109			334,168
Subscriptions received - shares to be issued		-			50,000
Accumulated deficit		(1,~~081~~979,~~588~~993	)		(751,390	)
Total Stockholders’ Deficit		(617,188	)		(366,275	)
Total Stockholders' Deficit		(1,484,885	)		(366,275	)
Total Liabilities and Stockholders’ Deficit	$	16,740		$	38,656
Total Liabilities and Stockholders' Deficit	$	303,050		$	38,656

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

3

Table of Contents

Sunset Island Group, Inc.

Condensed Consolidated ~~Statement~~Statements of Operations

(Unaudited)

	Three Months Ended						Six Months Ended
	January 31,
	April 30,						April 30,
	2018			2017			2018			2017
Revenue	$	-		$	-		$	-		$	-
Operating Expenses
Labor		~~184~~188,~~978~~980			-30,481			373,958			30,481
Supplies		2764,~~575~~508			-51,259			92,083			51,259
General and administrative expenses		42104,~~547~~299			~~980~~16,182			146,846			17,162
Lease		5453,~~930~~442			-11,500			108,372			11,500
Lab testing		~~250~~1,060			-			1,310			-
Utilities		335,~~467~~354			-			38,821			-
Professional fees		216,~~036~~296			-4,000			18,332			4,000
Total Operating Expenses		~~315~~463,~~783~~939			~~980~~113,422			779,722			114,402
Loss from operations		(~~315~~463,~~783~~939	)		(~~980~~113,422	)		(779,722	)		(114,402	)
Other Expenses
Other Income (Expense)
Interest expense		(14606,~~415~~457	)		-			(620,872	)		-
Net Loss	$	(330,198	)	$	(980	)
Net change in fair value of derivative liabilities including day one losses		223,378			-			223,378			-
Net loss per common share – basic and diluted	$	(0.06	)	$	(0.00	)
		(383,079	)		-			(397,494	)		-
Weighted average number of common shares outstanding		5,371,771			50,031,771
Net Loss	$	(847,018	)	$	(113,422	)	$	(1,177,216	)	$	(114,402	)
Net loss per common share – basic and diluted	$	(0.16	)	$	(0.00	)	$	(0.22	)	$	(0.00	)
Weighted average number of common shares outstanding		5,383,569			50,031,771			5,377,572			50,031,771

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

Table of Contents

Sunset Island Group, Inc.

Condensed Consolidated ~~Statement~~Statements of Stockholders’ ~~Equity (~~Deficit)

For the ~~three~~Six ~~months~~Months ~~ended~~Ended ~~January~~April 3130, 2018 ~~and 2017~~

(Unaudited)

									Additional			Common Stock
	Series A Preferred Stock				Common Stock				Paid-In			Subscription			Accumulated
	Shares		Amount		Shares		Amount		Capital			Received			Deficit			Total
Balance - October 31, 2017		4,600,000		460		4,871,771		487		334,168			50,000			(751,390	)		(366,275	)
Common stock issued for cash		-		-		500,000		50		49,950			(50,000	)		-			-
Beneficial conversion feature		-		-		-		-		9,444			-			-			9,444
Contribution		-		-		-		-		69,841			-			-			69,841
Net loss for the period		-		-		-		-		-			-			(330,198	)		(330,198	)
Balance - January 31, 2018		4,600,000	$	460		5,371,771	$	537	$	463,403		$	-		$	(1,081,588	)	$	(617,188	)
Common stock issued for note repayment		-		-		15,000		2		31,498			-			-			31,500
Reclassification of beneficial conversion feature to derivative liability from additional paid in capital		-		-		-		-		(9,444	)		-			-			(9,444	)
Contribution		-		-		-		-		8,652			-			-			8,652
Net loss for the period		-		-		-		-		-			-			(847,018	)		(847,018	)
Declaration of cash dividend		-		-		-		-		-			-			(51,387	)		(51,387	)
Balance - April 30, 2018		4,600,000	$	460		5,386,771	$	539	$	494,109		$	-		$	(1,979,993	)	$	(1,484,885	)

									Additional		Common Stock
	Series A Preferred Stock				Common Stock				Paid-In		Subscription		Accumulated
	Shares		Amount		Shares		Amount		Capital		Received		Deficit			Total
Balance - October 31, 2016		-	$	-		50,031,771	$	5,003	$	5,997	$	-	$	(10,030	)	$	970
Net loss for the period		-		-		-		-		-		-		(980	)		(980	)
Balance - January 31, 2017		-	$	-		50,031,771	$	5,003	$	5,997	$	-	$	(11,010	)	$	(10	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

The accompanying notes are an integral part of these condensed consolidated financial statements

Table of Contents

Sunset Island Group, Inc.

Condensed Consolidated Statements of ~~Cash~~Stockholders’ ~~Flows~~Equity (Deficit)

For the Six Months Ended April 30, 2017

(Unaudited)

	Three Months Ended
											Additional		Common Stock
	January 31,
	Series A Preferred Stock						Common Stock				Paid-In		Subscription		Accumulated
	2018			2017
	Shares			Amount			Shares		Amount		Capital		Received		Deficit			Total
Cash Flows From Operating Activities:
Balance - October 31, 2016		-		$	-			50,031,771	$	5,003	$	5,997	$	-	$	(10,030	)	$	970
Net loss	$	(330,198	)	$	(980	)
Net loss for the period		-			-			-		-		-		-		(980	)		(980	)
Adjustments to reconcile net loss to net cash used in operating activities
Balance - January 31, 2017		-		$	-			50,031,771	$	5,003	$	5,997	$	-	$	(11,010	)	$	(10	)
Amortization of debt discount		11,321			-
Net loss for the period		-			-			-		-		-		-		(113,422	)		(113,422	)
Change in operating assets and liabilities:
Balance - April 30, 2017		-		$	-			50,031,771	$	5,003	$	5,997	$	-	$	(124,432	)	$	(113,432	)
Accounts payable and accrued liabilities		(7,577	)		-
Accrued interest - related party		497			-
Net Cash Used in Operating Activities		(325,957	)		(980	)
Cash Flows From Financing Activities:
Bank overdraft		-			10
Repayment of promissory notes - related party		99,200			-
Contribution		69,841			-
Proceeds from convertible note		135,000			-
Net Cash Provided by Financing Activities		304,041			10
Net change in cash and cash equivalents		(21,916	)		(970	)
Cash and cash equivalents, beginning of period		24,656			970
Cash and cash equivalents, end of period	$	2,740		$	-
Supplemental cash flow information:
Cash paid for interest	$	-		$	-
Cash paid for taxes	$	-		$	-
Non-cash financing transactions:
Common stock issued	$	50,000		$	-
Beneficial conversion feature	$	9,444		$	-

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

Table of Contents

Sunset Island Group, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	Six Months Ended
	April 30,
	2018			2017

Cash Flows From Operating Activities:
Net loss	$	(1,177,216	)	$	(114,402	)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization of debt discount		505,145			-
Change in fair value of derivative liabilities		(223,378	)
Prepayment interest penalty		85,289
Change in operating assets and liabilities:
Deposit		-			(14,000	)
Accounts payable and accrued liabilities		(10,175	)		7,108
Accrued interest		27,480			-
Accrued interest - related party		3,109			-
Net Cash Used in Operating Activities		(789,746	)		(121,294	)

Cash Flows From Financing Activities:
Proceeds from promissory notes - related party		99,200			123,200
Contribution		78,493			-
Advancement from related party		900			-
Repayment to related party		(347	)		-
Proceeds from convertible note		1,152,250			-
Repayment of convertible note		(276,356	)		-
Net Cash Provided by Financing Activities		1,054,140			123,200

Net change in cash and cash equivalents		264,394			1,906
Cash and cash equivalents, beginning of period		24,656			970
Cash and cash equivalents, end of period	$	289,050		$	2,876

Supplemental cash flow information:
Cash paid for interest	$	-		$	-
Cash paid for taxes	$	-		$	-

Non-cash financing transactions:
Declaration of cash dividend	$	51,387		$	-
Derivative liabilities recognized as debt discount	$	707,669		$	-
Warrants issued in conjunction with convertible notes recognized as debt discount	$	444,581		$	-
Common stock issued for partial repayment of convertible note	$	31,500		$	-
Common stock issued for subscription received	$	50,000		$	-

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

Table of Contents

Sunset Island Group, Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – DESCRIPTION OF BUSINESS

Sunset Island Group, Inc. (“SIGO” or the “Company”) was originally incorporated in the State of Colorado on September 29, 2005 ~~under~~as Gulf West Property, Inc. On October 25, 2005 the Company changed its name ofto Titan Global Entertainment, Inc. On May 7, 2008, the Company changed its name to Sunset Island Group, Inc.

Our business and corporate address is ~~555~~20420 N.Spence ~~El Camino Real #A418~~Road, ~~San~~Salinas ~~Clemente~~ CA ~~82672~~93908, our phone number is (424) 239-6230. Our corporate website is www.sunsetislandgroup.com.

We have one subsidiary, VBF Brands, Inc. (“VBF Brands”), a California, corporation.

Our Business

The ~~State~~Company ofoperates ~~California~~its ~~requires~~cannabis ~~company~~growing, ~~engaged~~cultivation, inmanufacturing ~~the~~and ~~cannabis~~distribution ~~operations~~business through its wholly owned subsidiary VBF Brands. VBF Brands operated as a Nonprofit Mutual Benefit entity until December 21, 2017 when it was converted to bea ~~licensed~~For byProfit entity. Prior to December 21, 2017, VBF Brands operated as a collective under the ~~State~~Compassionate ofUse ~~California~~Act. ~~The~~Since VBF Brands was operating as a Nonprofit until December 21, 2017, the Company isdetermined ~~regulated~~that byit cannot book any revenue from the ~~following~~activities ~~entities~~associated inwhile ~~California~~it operated as collective under the Compassionate Use Act and as a non-profit. However, the Company will book the revenue generated by VBF Brands since December 21, 2017.

The ~~Bureau~~ ofCompany ~~Cannabis~~previously ~~Control~~ operated its cultivation business through its former wholly owned subsidiary Battle Mountain Genetics, Inc. (~~Bureau~~“BMG”); ishowever, upon the ~~lead~~conversion ~~agency~~of inVBF ~~regulating~~Brands ~~commercial~~to ~~cannabis~~a ~~licenses~~ for ~~medical~~profit ~~and~~entity ~~adult-use~~the ~~cannabis~~Company intransitioned ~~California.~~the ~~The~~operation ~~Bureau~~of isall ~~responsible~~of ~~for~~its ~~licensing~~cannabis ~~retailers,~~actives ~~distributors,~~through ~~testing~~VBF ~~labs, microbusinesses,~~Brands and ~~temporary~~BMG ~~cannabis~~ceased ~~events~~active operations.

~~CalCannabis~~Share Cultivation Licensing, a division of the California Department of Food and Agriculture (CDFA), ensures public safety and environmental protection by licensing and regulating commercial cannabis cultivators in California. Exchange

~~Manufactured~~BMG ~~Cannabis~~was ~~Safety~~incorporated ~~Branch,~~in athe ~~division~~State of ~~the~~ California ~~Department~~on ofSeptember ~~Public Health~~29, ~~(CDPH)~~2016. ~~MCSB~~On isOctober ~~responsible~~17, ~~for~~2016, ~~regulation~~the ofCompany ~~all~~entered ~~commercial~~into ~~cannabis~~an ~~manufacturing~~agreement inwhereby ~~California.~~it ~~MCSB~~acquired ~~strives~~100% toof ~~protect~~the ~~public~~issued ~~health~~ and ~~safety~~outstanding byshares ~~ensuring~~of ~~commercial~~capital ~~cannabis~~stock ~~manufacturers~~of ~~operate~~BMG ~~safe,~~in ~~sanitary~~exchange ~~workplaces~~for ~~and~~50,000,000 ~~follow~~shares ~~good manufacturing practices to produce products that are free~~ of ~~contaminants,~~SIGO ~~meet~~common ~~product guidelines and are properly packaged and labeled~~stock.

~~These~~Prior ~~three~~to ~~divisions~~the ~~require~~share ~~the~~exchange ~~company~~SIGO tohad ~~license~~no ~~packages~~assets, ~~and~~liabilities beor ~~compliant~~operations; ~~with~~following ~~all~~the ~~local,~~share ~~state~~exchange ~~and~~SIGO ~~environmental~~operated ~~regulations.~~BMG ~~The~~as ~~Company~~a ~~estimates~~wholly ~~that~~owned ~~the~~subsidiary. ~~cost~~Immediately ofprior ~~licensing~~to ~~each~~the ~~year~~share ~~will~~exchange bewith ~~approximately~~BMG’s ~~$50~~shareholders,~~000~~ -there ~~$100~~were 30,~~000~~894 ~~per~~shares ~~year.~~of ~~The~~SIGO ~~amount~~Common ~~will~~Stock ~~vary~~outstanding ~~year~~and tono ~~year~~shares ~~depending~~of onSIGO ~~what~~Preferred ~~changes~~Stock ~~have~~outstanding. ~~been~~After ~~made~~the toshare ~~regulations~~exchange, ~~and~~the ifCompany ~~any~~had ~~upgrades~~50,031,771 ~~would~~Common beshares ~~required~~outstanding toand beno ~~made~~shares onof ~~the~~Preferred ~~property~~Stock outstanding.

~~The~~Divestiture ~~Company currently is licensed by the State~~ of ~~California~~Battle ~~for~~Mountain ~~the~~Genetics, ~~following activities:~~Inc.

License Type		License Number
Cannabis Cultivation		PAL18-0000119(Provisional)
Cannabis Cultivation Nursery		TAL18-0008563
Medical Use Manufacturing License		CDPH-T00000243
Adult Use Manufacturing License		CDPH-T00000244
Adult Use and Medicinal Distribution		C11-0000102-LIC

During December 2017, the Company divested itself of BMG by transferring all of the issued and outstanding shares of BMG, to T.J. Magallanes a former officer and director of the Company, in exchange for 3,036,000 of Mr. Magallanes’ SIGO Series A Preferred shares.

The Company operates through its wholly owned subsidiary VBF Brands. VBF Brands operated as a Nonprofit Mutual Benefit entity until December 21, 2017 when it was converted to a For Profit entity. Prior to December 21, 2017, VBF Brands operated as a collective under the Compassionate Use Act. Since VBF Brands was operating as a Nonprofit until December 21, 2017, the Company determined that it cannot book any revenue from the activities associated while it operated as collective under the Compassionate Use Act and as a non-profit. However, the Company will book the revenue generated by VBF Brands since December 21, 2017. The Company previously was operating Battle Mountain Genetics; however, upon the conversion of VBF Brands to a for profit entity the Company has been operating all of its cannabis actives through VBF Brands and Battle Mountain Genetics ceased operations.

Reverse Merger

On October 17, 2016, the Company executed a reverse merger with Battle Mountain Genetics, Inc. On October 17, 2016, the Company entered into an Agreement whereby the Company acquired 100% of Battle Mountain Genetics, Inc, in exchange for 50,000,000 shares of Sunset Island Group common stock. Immediately prior to the reverse merger, there were 30,894 common shares outstanding and no shares of Preferred shares outstanding. After the reverse merger, the Company had 50,031,771 Common shares outstanding and no shares of Preferred shares outstanding.

Battle Mountain Genetics was incorporated in the State of California on September 29, 2016. Battle Mountain Genetics, Inc. was the surviving Company and became a wholly owned subsidiary of Sunset Island Group. Sunset Island Group had no operations, assets or liabilities prior to the reverse merger.

7 Table of Contents

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation of Interim Financial Statements

The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the ~~three~~six months ended ~~January~~April 3130, 2018 are not necessarily indicative of the results that may be expected for the year ending October 31, 2018. Notes to the unaudited interim condensed consolidated financial statements that would substantially duplicate the disclosures contained in the audited consolidated financial statements for fiscal year 2017 have been omitted. This report should be read in conjunction with the audited consolidated financial statements and the footnotes thereto for the fiscal year ended October 31, 2017 included in the Company’s 10-K as filed with the Securities and Exchange Commission on March 25, 2019.

Table of Contents

Consolidation Policy

The unaudited condensed consolidated financial statements of the Company include the accounts of the Company and its wholly owned subsidiary, VBF Brands, Inc. All significant intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates and Assumptions

The preparation of financial statements in accordance with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and cash equivalents

Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less, at the date acquired. As of ~~January~~April 3130, 2018 and October 31, 2017, cash primarily consists of cash in bank. As of ~~January~~April 3130, 2018 and October 31, 2017, cash was $2289,~~740~~050 and $24,656, respectively.

Basic and Diluted Net Loss Per Share of Common Stock

The Company has adopted ASC Topic 260, “Earnings per Share,” (“EPS”) which requires presentation of basic EPS on the face of the income statement for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic EPS computation. In the accompanying financial statements, basic earnings (loss) per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.

As at ~~January~~April 3130, 2018 and October 31, 2017, the Company has ~~potentially~~the ~~46,000,000~~following inpotentially dilutive securities, ~~from outstanding Series A convertible preferred stock,~~ which were excluded from the computation of diluted net loss per common share as the result of the computation was anti-dilutive.

	April 30,		October 31,
	2018		2017
Series A convertible preferred stock		46,000,000		46,000,000
Convertible Notes		1,328,172		-
Warrants		211,883		-
		47,540,055		46,000,000

Concentrations of Credit Risk

The Company’s financial instruments that are exposed to concentrations of credit risk primarily consist of its cash and cash equivalents and related party payables that it will likely incur in the near future. The Company places its cash and cash equivalents with financial institutions of high credit worthiness. At times, its cash and cash equivalents with a particular financial institution may exceed any applicable government insurance limits. The Company’s management plans to assess the financial strength and credit worthiness of any parties to which it extends funds, and as such, it believes that any associated credit risk exposures are limited.

89 Table of Contents

Financial Instruments

The Company follows ASC 820, “Fair Value Measurements and Disclosures,” which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

Level 1

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2

Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

Level 3

Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of January 31, 2018. The carrying values of our financial instruments, including, cash and cash equivalents, accounts payable and accrued expenses; and dividend payable and due to related party approximate their fair values due to the short-term maturities of these financial instruments.

The following table summarizes fair value measurements by level at April 30, 2018 and October 31, 2017, measured at fair value on a recurring basis:

April 30, 2018	Level 1		Level 2		Level 3		Total
Liabilities
Derivative Liabilities	$	-	$	-	$	928,872	$	928,872

October 31, 2017	Level 1		Level 2		Level 3		Total
Liabilities
Derivative Liabilities	$	-	$	-	$	-	$	-

Related Parties

The Company follows ASC 850, “Related Party Disclosures,” for the identification of related parties and disclosure of related party transactions. See notes 4.

Income Taxes

We account for income taxes under ASC 740 “Income Taxes.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.

910 Table of Contents

Revenue Recognition

The Company recognizes revenue in accordance with “Revenue from Contracts with Customers” (“ASC 606”). ASC 606 requires that the criteria must be met before revenue can be recognized:

The parties to the contract have approved the contract (in writing, orally, or in accordance with other customary business practices) and are committed to perform their respective obligations.

The Company can identify each party’s rights regarding the goods or services to be transferred.

The Company can identify the payment terms for the goods or services to be transferred.

The contract has commercial substance (that is, the risk, timing, or amount of the entity’s future cash flows is expected to change as a result of the contract).

It is probable that the Company will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. In evaluating whether collectability of an amount of consideration is probable, an entity shall consider only the customer’s ability and intention to pay that amount of consideration when it is due. The amount of consideration to which the entity will be entitled may be less than the price stated in the contract if the consideration is variable because the entity may offer the customer a price concession.

Research and Development Expenses

We follow ASC 730, “Research and Development,” and expense research and development costs when incurred. Accordingly, third-party research and development costs, including designing, prototyping and testing of product, are expensed when the contracted work has been performed or milestone results have been achieved. Indirect costs are allocated based on percentage usage related to the research and development.

~~Capitalization~~Leasehold improvements

~~Expenditures~~The ~~for~~company ~~repairs~~subleases ~~and~~land ~~maintenance~~shared ~~are~~with ~~charged~~other larger farms. In addition to ~~operating~~fixed ~~expense~~monthly aslease payments, the Company is required to pay a proportionate share of costs incurred for upgrades benefiting all lots. ~~Additions~~Expenditures for repairs and maintenance and betterments for improvements shared with neighboring properties, are ~~capitalized.~~charged to rent expense as incurred.

For the six months ended April 30, 2018 and 2017, additional leasehold costs included in rent expense were $34,468 and $0, respectively.

Recently Issued Accounting Standards

In June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (Topic 718), Improvements to Nonemployee Share-based Payments (“ASU 2018-07”). This ASU expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The effective date for the standard is for interim periods in fiscal years beginning after December 15, 2018, with early adoption permitted, but no earlier than the Company's adoption date of Topic 606. Under the new guidance, the measurement of nonemployee equity awards is fixed on the grant date. The new guidance is required to be applied retrospectively with the cumulative effect recognized at the date of initial application. The Company is currently evaluating the effect ASU 2018-07 will have on the consolidated financial statements.

10 Table of Contents

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. The ASU modifies the disclosure requirements in Topic 820, Fair Value Measurement, by removing certain disclosure requirements related to the fair value hierarchy, modifying existing disclosure requirements related to measurement uncertainty and adding new disclosure requirements, such as disclosing the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and disclosing the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. This ASU is effective for public companies for annual reporting periods and interim periods within those annual periods beginning after December 15, 2019. The Company is currently evaluating the effect, if any, that the ASU will have on its consolidated financial statements.

Table of Contents

In September 2017, the FASB has issued Accounting Standards Update (ASU) No. 2017-13, “Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842): Amendments to SEC Paragraphs Pursuant to the Staff Announcement at the July 20, 2017 EITF Meeting and Rescission of Prior SEC Staff Announcements and Observer Comments.” The amendments in ASU No. 2017-13 amends the early adoption date option for certain companies related to the adoption of ASU No. 2014-09 and ASU No. 2016-02. Both of the below entities may still adopt using the public company adoption guidance in the related ASUs, as amended. The effective date is the same as the effective date and transition requirements for the amendments for ASU 2014-09 and ASU 2016-02.

In May 2014, the FASB issued some accounting standards update which modifies the requirements for identifying, allocating, and recognizing revenue related to the achievement of performance conditions under contracts with customers. This update also requires additional disclosure related to the nature, amount, timing, and uncertainty of revenue that is recognized under contracts with customers. This guidance is effective for fiscal and interim periods beginning after December 15, 2017 and is required to be applied retrospectively to all revenue arrangements. The adoption of this guidance is not expected to have a significant impact on the Company’s consolidated financial statements.

In February 2017, the FASB has issued Accounting Standards Update (ASU) No. 2017-05, “Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610-20): Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets.” The amendments clarify that a financial asset is within the scope of Subtopic 610-20 if it meets the definition of an in substance nonfinancial asset. The amendments also define the term in substance nonfinancial asset. The amendments clarify that nonfinancial assets within the scope of Subtopic 610-20 may include nonfinancial assets transferred within a legal entity to a counterparty. For example, a parent may transfer control of nonfinancial assets by transferring ownership interests in a consolidated subsidiary. A contract that includes the transfer of ownership interests in one or more consolidated subsidiaries is within the scope of Subtopic 610-20 if substantially all of the fair value of the assets that are promised to the counterparty in a contract is concentrated in nonfinancial assets. The amendments clarify that an entity should identify each distinct nonfinancial asset or in substance nonfinancial asset promised to a counterparty and derecognize each asset when a counterparty obtains control of it. Effective at the same time as the amendments in Update 2014-09, Revenue from Contracts with Customers (Topic 606). Therefore, public business entities, certain not-for-profit entities, and certain employee benefit plans should apply the amendments in this Update to annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. All other entities should apply the amendments in this Update to annual reporting periods beginning after December 15, 2018, and interim periods within annual periods beginning after December 15, 2019.

In January 2017, the FASB has issued Accounting Standards Update (ASU) No. 2017-04, “Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment.” These amendments eliminate Step 2 from the goodwill impairment test. The annual, or interim, goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax -deductible goodwill on the carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable. The amendments also eliminate the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. Effective for public business entities that are SEC filers for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. ASU 2017-04 should be adopted on a prospective basis. The Company does not anticipate the adoption of ASU 2017-04 will have a material impact on its consolidated financial statements.

1112 Table of Contents

In January 2017, the FASB issued ASU No. 2017-01, “Business Combinations (Topic 805): Clarifying the Definition of a Business.” This new standard clarifies the definition of a business and provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This new standard will be effective for the Company on January 1, 2018, however, early adoption is permitted with prospective application to any business development transaction.

Management has considered all recent accounting pronouncements issued. The Company’s management believes that these recent pronouncements will not have a material effect on the Company’s financial statements.

NOTE 3 – GOING CONCERN

The Company’s financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not established any source of revenue to cover its operating costs, and it does not have sufficient cash flow to maintain its operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

The Company expects to develop its business and thereby increase its revenue. However, the Company would require sufficient capital to be invested into the Company to acquire the properties to begin generating sufficient revenue to cover the monthly expenses of the Company. Until the Company is able to generate revenue, the Company would be required to raise capital through the sale of its stock or through debt financing. Management may raise additional capital through future public or private offerings of the Company’s stock or through loans from private investors, although there can be no assurance that it will be able to obtain such financing. The Company’s failure to do so could have a material and adverse effect upon it and its shareholders.

To this date the Company has relied on the sale of securities to finance its operations and growth. The Company expects to continue to fund the Company through debt and securities sales and issuances until the Company generates enough revenues through the operations. These transactions will initially be through related parties, such as the Company’s officers and directors.

NOTE 4 – RELATED PARTY TRANSACTIONS

~~Note~~Notes Payable

During the three months ended January 31, 2018, the Company issued ~~various~~multiple 5% notes to a related party, for gross proceeds of $99,200. The notes are due on December 31, 2019. The notes accrue interest at 0% for the initial nine months and then 5% on annual rate thereafter.

12During ~~Table~~the year ended October 31, 2017, the Company issued a total of ~~Contents~~twenty-six (26) 5% notes to Novus Group, a related party, for gross proceeds of $363,200 (together the “Novus Notes”). The Novus Notes contained maturity dates of December 31, 2018 and December 31, 2019. The Novus Notes accrue interest at 0% for the initial nine months and 5% on annual rate thereafter.

~~During~~As ~~the~~of ~~year~~April ~~ended~~30, 2018 and October 31, 2017, the ~~Company~~long ~~issued~~term ~~various~~portion 5%of notes topayable ~~Novus~~were ~~Group~~$272,200 ~~for~~and ~~gross proceeds of~~ $~~363~~330,200., ~~The~~respectively, ~~notes~~and ~~are~~the ~~due~~current onportion ~~December~~of ~~31,~~notes ~~2018~~payable orwere ~~December~~$157,200 31and $0, ~~2019~~respectively. ~~The~~During ~~notes~~the ~~accrue~~six ~~interest~~months atended 0%April ~~for~~30, 2018 and 2017, the ~~initial~~notes ~~nine~~payable ~~months~~incurred ~~and~~interest ~~then~~expense 5%of on$3,109 ~~annual~~and ~~rate~~$0, ~~thereafter~~respectively.

As of January 31, 2018 and October 31, 2017, the notes payable were $272,200 and $330,200 and current portion of notes payable were $157,200 and $0, respectfully. During the three months ended January 31, 2018, the notes payable incurred interest expense of $497.

Due to Related Party

During the period beginning January, 2017 and ending in October, 2017, Valerie Baugher, an officer of the Company lent to the Company, pursuant to seven (7) total advancements, an aggregate of $7,173 for use as working capital (collectively the “Officer Loans”). During the six months ended April 30, 2018, the Company received advances from an officer of the Company at the amount of $900 and repaid to her $347. The ~~loans~~Officer Loans are due on demand and non-interest bearing. As of ~~January~~April 3130, 2018 and October 31, 2017, the total remaining due to the officer was $3,438 and $2,885, respectively.

~~NOTE~~13 5Table –of ~~DIVIDEND PAYABLE~~Contents

OnNOTE ~~August~~5 ~~30,~~– ~~2017,~~CONVERTIBLE ~~the Company filed with FINRA its corporate notice for the cash dividend.~~NOTES

AsThe ofCompany ~~January~~had ~~31,~~the ~~2018~~following ~~and~~principal ~~October~~balance ~~31,~~under ~~2017,~~its ~~the~~convertible ~~dividend~~notes ~~payable~~outstanding ~~was~~as ~~$46~~of April 30,~~029.~~ 2018:

NOTE 6 – STOCKHOLDERS’ EQUITY

	April 30,
	2018
Convertible Notes - originated in December 2017	$	170,000
Convertible Notes - originated in February 2018		945,000
		1,115,000
Less debt discount and debt issuance cost		(829,855	)
		285,145
Less current portion of convertible notes payable		(285,145	)
Long-term convertible notes payable	$	-

The Company recognized amortization expense related to the debt discount and deferred financing fees of $505,145 for the six months ended April 30, 2018, which is included in interest expense in the statements of operations.

For the six months ended April 30, 2018, the interest expense on convertible notes was $27,479, with repayment on accrued interest of $2,567 from a note settlement during the period. As of April 30, 2018, the accrued interest payable was $24,913.

During the six months ended April 30, 2018, the Company repaid a convertible note of $220,000 for a total repayment of $276,356 and issuance of 15,000 shares of common stock, resulting in repayment interest penalty of $85,290.

Convertible Notes – Issued during the six months ended April 30, 2018

During the six months ended April 30, 2018, the Company issued convertible notes in the total principal amount of $1,335,000 in exchange for cash proceeds of $1,152,250, after deducting original issuance discounts of $120,750 and financing fees of $62,000. The convertible notes were also provided with warrants to purchase up to 211,883 shares of common stock at exercise price of $1.90 per share. The terms of convertible notes are summarized as follows:

	·	Term ranging from six months to one year. Notes expire on July 8, 2018 and February 13, 2019;
	·	Annual interest rates ranging from 10% to 12%;
	·	Convertible at the option of the holders at issuance; and
	·	Conversion prices are typically based on a fixed price ranging from $0.90 to $1.70. However, in the event the market capitalization falls below the minimum market capitalization at any time, the conversion price is the lower of the note fixed conversion price or the market price as of the applicable date of conversion.

The Company recognized amortization expense related to the debt discount and debt issuance cost of $196,767 for the six months ended April 30, 2018, which is included in interest expense in the statements of operations.

For the six months ended April 30, 2018, the interest expense on the convertible note was $18,113. As of April 30, 2018, the accrued interest payable was $18,113.

NOTE 6 – DERIVATIVE LIABILITIES

The Company analyzed the conversion option for derivative accounting consideration under ASC 815, “Derivatives and Hedging,” and determined that the convertible notes should be classified as a liability since the conversion option becomes effective at issuance resulting in there being no explicit limit to the number of shares to be delivered upon settlement of the above conversion options. The Company accounts for warrants and Series A Convertible Preferred Stock as a derivative liability due to there being no explicit limit to the number of shares to be delivered upon settlement of all conversion options.

Table of Contents

The Company determined our derivative liabilities to be a Level 3 fair value measurement and used the Black-Scholes pricing model to calculate the fair value as of April 30, 2018. The Black-Scholes model requires six basic data inputs: the exercise or strike price, time to expiration, the risk-free interest rate, the current stock price, the estimated volatility of the stock price in the future, and the dividend rate. Changes to these inputs could produce a significantly higher or lower fair value measurement. The fair value of each convertible note and warrant is estimated using the Black-Scholes valuation model. The following weighted-average assumptions were used during the six months ended April 30, 2018:

		Six months ended
		April 30,
		2018
Expected term		0.58 - 1 years
Expected average volatility		180% - 268%
Expected dividend yield		-
Risk-free interest rate		1.64% - 2.14%

The following table summarizes the derivative liabilities included in the balance sheet at April 30, 2018:

Fair Value Measurements Using Significant Observable Inputs (Level 3)
Balance - October 31, 2017	$	-
Addition of new derivative liabilities recognized upon issuance of convertible notes and warrants as debt discount		1,152,250
Addition of new derivative liabilities recognized as day one loss on derivatives		1,043,494
Gain on change in fair value of the derivative liabilities		(1,266,872	)
Balance - April 30, 2018	$	928,872

The following table summarizes the gain on derivative liability included in the income statement for the six months ended April 30, 2018.

	Six months ended
	April 30,
	2018
Addition of new derivative liabilities recognized as day one loss on derivatives from convertible notes	$	1,043,494
Gain on change in fair value of the derivative liabilities		(1,266,872	)
	$	(223,378	)

NOTE 7 – DIVIDEND PAYABLE

On August 22, 2017, the Company declared a dividend, in the aggregate amount of $50,672, payable to the Common shareholders. On August 30, 2017, the Company filed with FINRA its corporate notice for a cash dividend. Of the total amount of the declared dividend, the amount of $4,463 was paid out to the Common shareholders.

On February 26, 2018, the Company’s Board of Directors approved a cash dividend payable to the Common shareholders and Series A Preferred shareholders. The record date for the dividend of $51,387 was March 31, 2018 at a rate of $0.001 per share.

As of April 30, 2018 and October 31, 2017, the aggregate dividend payable to Common and Series A Preferred shareholders was $46,029.

Table of Contents

NOTE 8 – STOCKHOLDERS’ EQUITY

Preferred Stock

The Company has authorized 15,000,000 preferred shares with a par value of $0.0001 per share. The Board of Directors is authorized to divide the authorized shares of Preferred Stock into one or more series, each of which shall be so designated as to distinguish the shares thereof from the shares of all other series and classes.

Series A Preferred Stock

The Company has designated 4,600,000 shares of Series A Convertible Preferred Stock. The Series A Preferred Stock may convert into Common Stock at a rate equal to 10 shares of common stock for each share of Series A Preferred stock. Each Series A Preferred shareholder is entitled to vote, on par with the Common shareholders, one (1) vote for each share of Common Stock into which a Series A Preferred share may be converted. In the event that any cash dividend on the Common Stock is declared by the Board, the Board shall simultaneously declare a dividend for each share of Series A Preferred Stock in an amount equal to the product of (i) the per share dividend declared and to be paid in respect of each share of Common Stock and (ii) the amount of common stock the Series A Preferred Stock is convertible into under the designation.

As at ~~January~~April 3130, 2018 and October 31, 2017, the Company had 4,600,000 shares of Series A Preferred Stock issued and outstanding.

Series B Preferred Stock

The Company has designated 8,000,000 shares of Series B Preferred Stock, with a face value of $1.00 per share. The Series B Preferred Stock has no conversion ~~right~~rights or no voting rights. The shareholders of the Series B Preferred will be entitled to a payment of $200 per pound that the Company ~~harvested~~harvests from its cultivation operations, which is divided by the outstanding shares of the Series B preferred shares.

As at ~~January~~April 3130, 2018 and October 31, 2017, the Company had no shares of Series B Preferred Stock issued and outstanding.

13 Table of Contents

Series C Preferred Stock

The Company has designated 500,000 shares of Series C Convertible Preferred Stock. The Series C Preferred Stock has no voting rights. The Series C Preferred Stock may convert into Common Stock at a rate equal to 10 shares of common stock for each share of Series C Preferred stock. Each Series C Preferred shareholder is entitled to vote, on par with the Common shareholders, one (1) vote for each share of Common Stock into which a Series C Preferred share may be converted. In the event that any cash dividend on the Common Stock is declared by the Board, the Board shall simultaneously declare a dividend for each share of Series C Preferred Stock in an amount equal to the product of (i) the per share dividend declared and to be paid in respect of each share of Common Stock and (ii) the amount of common stock the Series C Preferred Stock is convertible into under the designation.

As at ~~January~~April 3130, 2018 and October 31, 2017, the Company had no shares of Series C Preferred Stock issued and outstanding.

Common Stock

~~The~~As a result of an amendment to the Company’s Articles of Incorporation filed with the Colorado Secretary of State’s office on March 14, 2018, SIGO has authorized 27,000,000 common shares with a par value of $0.0001 per share. Each ~~common~~Common share entitles the holder to one vote, in person or proxy, on any matter on which action of the stockholders of the corporation is sought.

During the ~~three~~six months ended ~~January~~April 3130, 2018, the Company issued 500,000 shares of common stock for $50,000 recorded as subscription received at October 31, 2017.

AsOn atFebruary ~~January 31~~20, 2018, ~~and~~the ~~October~~Company ~~31,~~issued ~~2017~~15,000 ~~the~~shares ~~Company~~of ~~had~~common 5stock valued at $31,~~371,771~~500 ~~and~~to 4Auctus Funds,~~871,771~~ ~~shares~~LLC ofas ~~common~~partial ~~stock~~repayment for the convertible note issued ~~and~~on ~~outstanding~~February 1, ~~respectively~~2018.

~~Additional~~As ~~paid~~at inApril ~~capital~~30, 2018 and October 31, 2017, the Company had 5,386,771 and 4,871,771 shares of Common Stock issued and outstanding, respectively.

~~During~~16 ~~the~~Table ~~three months ended January 31, 2018, the Company’s officer contributed additional paid in capital in the amount~~ of ~~$69,841.~~Contents

~~NOTE~~Warrants 7Exercisable –to ~~COMMITMENTS~~Common ~~AND CONTINGENCIES~~Shares

OnThe ~~March~~below 1,table ~~2017,~~summarizes the ~~Company~~activity ~~executed~~of awarrants ~~lease~~exercisable for ~~12,000~~common ~~square~~shares ~~feet~~during ~~green house space and 1,000 square of warehouse space expiring March 31, 2020. The monthly lease is $7,000 per month. During~~ the ~~three~~six months ended ~~January~~April 3130, 2018~~, we incurred total lease expenses of $54,930.~~:

The Company has aggregate future minimum lease commitments as of October 31, 2017, as follows:

	Number of Shares		Weighted- Average Exercise Price
Balances as of October 31, 2017		-	$	-
Granted		211,883		1.90
Exercised		-		-
Forfeited		-		-
Balances as of April 30, 2018		211,883	$	1.90

Year ending October 31,
2018	$	84,000
2019		84,000
2020		35,000
Total	$	203,000

The fair value of each warrant on the date of grant is estimated using the Black-Scholes option valuation model. The following weighted-average assumptions were used for options granted during the period ended April 30, 2018:

NOTE 8 – SUBSEQUENT EVENTS

	Six months ended
	April 30,
	2018
Exercise price	$	1.90
Remaining contractual term		5
Expected average volatility	280% - 293%
Expected dividend yield		-
Risk-free interest rate	2.60% - 2.79%

~~On February 1, 2018, the Company issued a convertible promissory note for $220,000.~~ The ~~note~~following istable ~~repayable~~summarizes ininformation ~~six~~relating months and bears interest at 12% per annum. The note is convertible into common shares at the option of the holder at issuance based on the discounted (50% discount) lowest trading prices of the Company’s shares during 25 days prior to ~~the conversion. On February 20, 2018, Auctus Fund was repaid for the loan and as such it is no longer~~ outstanding and ~~has~~exercisable ~~been~~warrants ~~retired.~~as ~~The Company had the right to prepay the note at 135% or negotiated the rate down to 125% plus 15,000 shares~~ of ~~restricted~~April ~~stock. The repayment amount was $276~~30,~~627~~ ~~plus 15,000 shares of restricted stock.~~2018:

14 Table of Contents

Warrants Outstanding

Warrants Exercisable

Weighted Average

Number

Remaining Contractual

Weighted Average

Number

Weighted Average

of Shares

life (in years)

Exercise Price

of Shares

Exercise Price

211,883

4.79

1.90

211,883

1.90

OnAggregate ~~February~~intrinsic ~~13,~~value ~~2018,~~is the ~~Company~~sum ~~has executed an agreement with St George Investments for $4,245,000 with the initial tranche being $850,000. This note carries an original issuance discount~~ of ~~$385,000 and~~ the ~~Company~~amounts ~~agreed~~by towhich ~~pay financing fees of $10,000. The note is repayable in one year and bears interest at 10% per annum. The note is convertible into common shares after six months from~~ the ~~issuance~~quoted ~~based~~market onprice ~~the discounted (50% discount) lowest trading prices~~ of the Company’s ~~shares~~stock ~~during~~exceeded ~~25 days prior to~~ the ~~conversion.~~exercise ~~This~~price ~~Note shall be comprised~~ of ~~thirteen~~the ~~(13)~~warrants ~~tranches~~at ~~(each,~~April ~~a “Tranche”)~~30, ~~consisting~~2018 offor ~~(i)~~those anwarrants ~~initial~~for ~~Tranche~~which inthe anquoted ~~amount~~market ~~equal~~price towas ~~$945,000~~in ~~and~~excess ~~any interest, costs, fees or charges accrued thereon or added thereto under the terms~~ of ~~this Note and~~ the ~~other~~exercise ~~Transaction~~price ~~Documents~~ (~~as defined~~ “in -the ~~Purchase Agreement) (the “Initial Tranche~~-money”), ~~and (ii~~warrants). ~~twelve~~As ~~(12) additional Tranches, each in the amount~~ of ~~$275,000.00,~~April ~~plus any interest~~30, ~~costs~~2018, ~~fees~~the oraggregate ~~charges~~intrinsic ~~accrued~~value ~~thereon or added thereto under the terms~~ of ~~this~~warrants ~~Note~~outstanding ~~and~~was ~~the~~approximately ~~other~~$0 ~~Transaction~~based ~~Documents~~on ~~(each, a “Subsequent Tranche”). The Initial Tranche shall correspond to~~ the ~~Initial~~closing ~~Cash~~market ~~Purchase~~price ~~Price,~~of $~~85,000~~0.008395 ofon ~~the~~April ~~OID and the Transaction Expense Amount~~30, ~~and may be converted into shares of Common Stock (as defined below) any time subsequent to the Purchase Price Date~~2018.

OnThe ~~February~~Company ~~20,~~determined ~~2018,~~that the ~~Company~~warrants ~~received~~qualify ~~the~~for ~~first~~derivative ~~tranche~~accounting ~~from~~as ~~St.~~a ~~George~~result ~~Investments, for net proceeds~~ of ~~$850,000.~~the Asrelated ~~part~~issuances of ~~the~~convertible ~~initial tranche~~notes, ~~the~~which ~~Company~~led ~~repaid~~to ~~Auctus~~no ~~Fund.~~explicit Onlimit ~~February~~to ~~20, 2018,~~ the ~~Company~~number ~~issued~~of ~~15,000~~ shares ~~of common stock~~ to ~~Auctus~~be ~~Funds,~~delivered ~~LLC~~upon asfuture ~~partial~~settlement ~~repayment~~of ~~for~~ the ~~convertible~~conversion ~~note~~options ~~issued~~(see onNote ~~February 13, 2018~~6). ~~The total repayment amount was $276,627 and 15,000 shares of common stock.~~

On17 ~~February~~Table ~~26, 2018, the Company’s Board~~ of ~~Directors approved a cash dividend. The record date for the dividend is March 31, 2018 at a rate of $0.001 per share.~~Contents

OnAdditional ~~February~~Paid ~~28,~~in ~~2018, the Company issued 360,006 shares of common stock to Greg Tucker for consulting services. The shares were cancelled on July 18, 2018.~~Capital

OnDuring ~~March 2, 2018.~~ the ~~Company~~six ~~has~~months ~~agreed~~ended toApril ~~terms~~30, ~~with REI Extracts regarding an extraction and distribution joint venture. Equipment has been ordered and is being shipped to the Company’s location in Salinas~~2018, ~~California. The operations of~~ the ~~joint venture will be conducted under the~~ Company’s ~~licenses.~~officer ~~Additionally,~~contributed ~~the~~additional ~~Company~~paid ~~has~~in ~~retained~~capital ~~REI~~in ~~Extracts to provide consulting services related to cultivation and to provide a master grower. The new master grower has been working with~~ the ~~Company~~amount ~~since January 2018. The grower will be paid based on the yield~~ of ~~sellable flower per bay~~$78,493. ~~The incentive pay shall be paid as follows:~~

NOTE 9 – COMMITMENTS AND CONTINGENCIES

On March 1, 2017, the Company executed a lease for 12,000 square feet green house space and 1,000 square of warehouse space expiring March 31, 2020. The base lease amount is $7,000 per month. On May 1, 2017, the Company executed a lease for 10,000 square feet of open land expiring June 30, 2020. The base lease amount is $2,576 per month. Any amounts expended by the Landlord for maintenance, repairs or improvements deemed to be our responsibility are added to our monthly lease amount as additional rent. During the six months ended April 30, 2018, we incurred total lease expenses of $69,312.

The Company has aggregate future minimum lease commitments as of April 30, 2018, as follows:

Year ending October 31,
2018	$	57,456
2019		114,912
2020		55,608
Total	$	227,976

NOTE 10 – SUBSEQUENT EVENTS

On July 8, 2018, the $170,000 convertible promissory note to St. George Investments, LLC issued on December 8, 2017 went into default and is accruing interest at a rate of 22%. The note is now convertible at a price which is the lower of $0.90 per share and the market price on any applicable date of conversion. Certain other reset provisions and potential true up policies are in effect which may materially increase the number of Common shares to be delivered upon conversion.

On March 2, 2018. the Company agreed to terms with REI Extracts regarding an extraction and distribution joint venture conducted under the Company’s licenses. To carry out the purposes of the joint venture, REI delivered equipment to SIGO’s facilities to conduct extraction tests. Additionally, REI Extracts also provided consulting services related to cultivation and provided a master grower. The new master grower originally began working with the Company in January 2018. The Company agreed to pay the grower based on the yield of sellable flower per warehouse bay, as follows:

Harvested pounds per bay of sellable flower		Incentive Bonus
0-40		$0
40-60		$40 per pound in excess of 40 pounds
60-80		$70 per pound in excess of 40 pounds
80-100		$100 per pound in excess of 40 pounds
100+		$120 per pound in excess of 40 pounds

OnIn ~~November 30~~December, 2018, ~~the~~SIGO ~~Company~~and ~~issued~~REI ~~333,000~~Extracts ~~shares~~mutually ofagreed ~~Series C Preferred Stock, valued at $1,000,000,~~ to ~~Job~~terminate ~~Growing~~their ~~Inc.~~joint ~~(“Job Growing”), for 50% of the profits of Job Growing~~venture. InAll ~~the~~equipment ~~event~~delivered ~~that~~by ~~Job~~REI ~~Growing~~Extracts ~~either:~~was ~~(i)~~removed ~~files a Registration Statement to become a reporting company under the Securities Exchange Act of 1934 which becomes effective, or (ii) is acquired~~ by anREI ~~unrelated~~Extracts ~~third~~and ~~party, then Sunset Island Group has~~ the ~~right~~Company toceased ~~buy~~utilizing ~~a Fifty Percent (50%) equity interest in~~ the ~~Job~~master ~~Growing~~grower ~~for~~provided ~~One~~by ~~Dollar~~REI ~~($1~~Extracts.~~00).~~

On18 ~~February~~Table ~~11, 2019, the Company issued 333,000 shares~~ of Series C Preferred Stock, valued at $1,000,000, to Cicero Travel Group Inc. (“Cicero Travel”) for 33% interest in the net profits of Cicero Travel, 19% equity interest in the common stock of Cicero Travel and the right to purchase an additional 14% equity interest in the common stock of Cicero Travel.Contents

15On ~~Table~~November 30, 2018, pursuant to a purchase agreement entered into by and between SIGO and Job Growing, Inc. (“Job Growing”) the Company issued 333,000 shares of ~~Contents~~Series C Preferred Stock, valued at $1,000,000, to Job Growing, in exchange for the rights to 50% of the net profits of Job Growing. In the event that Job Growing either: (i) files a registration statement, with the Securities and Exchange Commission (the “SEC”), to become a reporting company under the Securities Exchange Act of 1934; or (ii) is acquired by an unrelated third party, then SIGO has the right to buy a fifty percent (50%) equity interest in Job Growing for the additional consideration of one and no/100 dollar ($1.00).

On September 17, 2019 Job Growing notified the Company of its intent to terminate the agreement between Job Growing and the Company effective immediately.

On August 15, 2019, the Company received a true up notice from Job Growing to issue 576,091 shares of Series C Preferred Stock to Job Growing valued at $633,700, pursuant to the terms of the purchase agreement signed on November 30, 2018.

On January 15, 2019, BMG was fined approximately $35,000 for not having Worker's Compensation insurance for the months of January 2018 - April 2018. The Company believes this is a fine owed by BMG and is not a liability due to the Company, as we transferred ownership of BMG during December 2017, to T.J. Magallanes, the Company's former CEO (see Note 1). VBF Brands, the Company's operating entity, has worker’s compensation and was not subject to the fine. The Company ceased operating BMG in December 2017.

On February 11, 2019, pursuant to a purchase agreement entered into by and between SIGO and Cicero Travel Group, Inc. (“Cicero Travel”) the Company issued 333,000 shares of Series C Preferred Stock, valued at $1,000,000, to Cicero Travel, in exchange for the rights to receive 33% of the net profits of Cicero Travel, 19% of the issued and outstanding shares of the common stock of Cicero Travel and the right to purchase an additional 14% of the issued and outstanding shares of the common stock of Cicero Travel.

On August 19, 2019, the Company received a true up notice from Cicero Travel to issue 486,672 shares of Series C Preferred Stock to Cicero Travel valued at $593,740, pursuant to the terms of the purchase agreement signed on February 11, 2019. The Company believes the true up notice is without merit, that Cicero Travel has not met its obligations under the purchase agreement and SIGO intends to cancel the previously issued shares of Series C Preferred Stock and will not be issuing any additional shares of Series C Preferred Stock to Cicero Travel.

Subsequent to April 30, 2018 and through the date that these financials were issued, the Company received net proceeds of $1,034,400, net of total OID of $103,440, from St. George investments in regards to the purchase agreement and convertible note of $4,245,000 executed on February 13, 2018.

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition or Plan of Operation

FORWARD-LOOKING STATEMENTS

This quarterly report contains forward-looking statements. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Our interim unaudited consolidated financial statements are prepared in accordance with United States Generally Accepted Accounting Principles (“GAAP”). The following discussion should be read in conjunction with our condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed below and elsewhere in this quarterly report.

In this quarterly report, unless otherwise specified, all dollar amounts are expressed in United States dollars and all references to “common shares” refer to the common shares in our capital stock.

As used in this quarterly report, the terms “we”, “us”, “our” and “our ~~company~~Company” mean Sunset Island Group, Inc. and our wholly owned subsidiary, VBF Brands, Inc., a California corporation, unless otherwise indicated.

General Overview

Our business and corporate address is ~~555~~20420 NSpence Rd., ~~El Camino Real #A418~~Salinas, ~~San Clemente~~ CA ~~82672~~93908, our phone number is (424) 239-6230. Our corporate website is www.sunsetislandgroup.com/.

Until December 31, 2017, we operated ~~under~~our business through our then wholly owned subsidiary, Battle Mountain Genetics, Inc., a California corporation (“BMG”). The Company ~~operates~~currently conducts its business operations through its wholly owned subsidiary VBF Brands, Inc. ("VBF Brands" or “VBF”). VBF Brands operated as a ~~Nonprofit~~nonprofit ~~Mutual~~mutual ~~Benefit~~benefit entity until December 21, 2017 when it was converted to a ~~For~~for ~~Profit~~profit entity. Prior to December 21, 2017, VBF Brands operated as a collective ~~under~~pursuant ~~the~~to California’s Compassionate Use Act. Upon the conversion of VBF Brands to a for profit entity the Company ~~has~~began ~~been~~ operating all of its cannabis ~~actives~~related business through VBF Brands and BMG ceased active operations. One hundred percent of the ~~business~~issued ~~under~~and ~~Battle~~outstanding ~~Mountain~~shares ~~Genetics~~of BMG’s capital stock was transferred, ~~Inc~~in December, 2017 to T.J. ~~was~~Magallanes, ~~wound~~a ~~down~~former officer and director of SIGO.

We have one subsidiary, VBF Brands, Inc., a California, corporation.

We have never declared bankruptcy, been in receivership, or involved in any kind of legal proceeding.

Our Current Business

Our principal line of business is the growing, cultivation, production and distribution of ~~medical~~adult and medicinal cannabis.

1620 Table of Contents

The Company ~~has~~currently ~~leased~~leases ~~green~~the ~~house~~following ~~space~~real property in Northern California~~. The Company currently leases the following~~: greenhouse space of approximately 12,000 square feet; ~~bare~~vacant land of approximately 10,000 square feet that can ~~rebuilt~~developed for additional greenhouse use; ~~approximately~~and 2,~~000~~400 square feet ~~of nursery greenhouse space; 1,200 square feet~~ for drying, ~~and~~ curing, ~~approximately 400 square feet used for~~ manufacturing, ~~operations; approximately 500 square feet for its~~ trimming ~~activities;~~ and ~~approximately 300 square feet for its~~ distribution activities.

~~The~~Federal ~~State~~Regulation ~~of California requires company engaged in the cannabis operations to be licensed by the State of California. The Company is regulated by the following entities in California~~

The Company, by and through VBF (a wholly owned subsidiary) engages in the direct growth, cultivation, harvesting and distribution of cannabis containing psychoactive amounts of the THC molecule, for use in the medicinal cannabis industry

Cannabis is illegal under federal law and is a “Schedule 1” drug under the Controlled Substances Act (21 U.S.C. § 811) (the “CSA”). As a Schedule 1 drug, cannabis is viewed as being highly addictive and having no medical value. The United States Drug Enforcement Agency (“DEA”) enforces the CSA, and persons violating it are subject to federal criminal prosecution. The criminal penalty structure in the CSA is determined based on the specific predicate violations, including but not limited to: simple possession, drug trafficking, attempt and conspiracy, distribution to minors, trafficking in drug paraphernalia, money laundering, racketeering, environmental damage from illegal manufacturing, continuing criminal enterprise, and smuggling. A first conviction under the CSA can generally result in possible fines from $250,000 to $50 million dollars, and incarceration for periods generally from five and up to forty years. For a second conviction, fines increase generally from $500,000 to $75 million dollars, and incarceration for periods generally from ten years to twenty years to life.

The federal government recently issued guidance to federal prosecutors concerning marijuana enforcement under the CSA. On January 4, 2018, Attorney General Jeff Sessions issued a memorandum for all United States Attorneys concerning federal cannabis enforcement generally. The Department of Justice (the “DOJ”) rescinded all previous prosecutorial guidance issued by it regarding cannabis, including the August 29, 2013 memorandum by James Cole, then Deputy Attorney General (the “Cole Memorandum”).

The Cole Memorandum previously set out the DOJ’s prosecutorial priorities in light of various states legalizing cannabis for medicinal and/or recreational use. The Cole Memorandum provided that when states have implemented strong and effective regulatory and enforcement systems to control the cultivation, distribution, sale, and possession of cannabis, conduct in compliance with those laws and regulations is less likely to threaten the federal priorities. A strong and effective regulatory system, according to the Cole Memorandum, would affirmatively address federal priorities by, for example, implementing effective measures to prevent diversion of cannabis outside of the regulated system and to other states, prohibiting access to cannabis by minors, and replacing an illicit cannabis trade that funds criminal enterprises with a tightly regulated market in which revenues are tracked and accounted for. In such circumstances, consistent with the traditional allocation of federal-state efforts in this area, the Cole Memorandum provided that enforcement of state law by state and local law enforcement and regulatory bodies should remain the primary means of addressing cannabis-related activity. If state enforcement efforts did not protect against the harms set forth above, the federal government could seek to challenge the regulatory structure itself in addition to continuing to bring individual enforcement actions, including criminal prosecutions, focused on those harms.

The rescission of the Cole Memorandum created material uncertainty as it relates to how the DOJ will evaluate cannabis cases for prosecution and introduced risk into the Company’s business as it relates to the research, growth, cultivation, development, manufacturing, marketing and sale of its cannabis products.

Current guidance requires U.S. Attorneys to decide whether or not to pursue prosecution of cannabis activity based upon factors including: the seriousness of the crime, the deterrent effect of criminal prosecution, and the cumulative impact of particular crimes on the community. The guidance reiterates that the cultivation, distribution and possession of cannabis continues to be a crime under the CSA.

On March 23, 2018, President Donald J. Trump signed into law a $1.3 trillion-dollar spending bill that included an amendment known as “Rohrabacher-Blumenauer,” which prohibits the DOJ from using federal funds to prevent certain states “from implementing their own State laws that authorize the use, distribution, possession or cultivation of medical marijuana.”

Table of Contents

The United States Food & Drug Administration (the “FDA”) is generally responsible for protecting the public health by ensuring the safety, efficacy, and security of (1) prescription and over the counter drugs; (2) biologics including vaccines, blood & blood products, and cellular and gene therapies; (3) foodstuffs including dietary supplements, bottled water, and baby formula; and, (4) medical devices including heart pacemakers, surgical implants, prosthetics, and dental devices.

Regarding its regulation of drugs, the FDA process requires a review that begins with the filing of an “Investigational New Drug” (IND) application, with follow on clinical studies and clinical trials that the FDA uses to determine whether a drug is safe and effective, and therefore subject to approval for human use by the FDA.

Aside from the FDA’s mandate to regulate drugs, the FDA also regulates dietary supplement products and dietary ingredients under the Dietary Supplement Health and Education Act of 1994. This law prohibits manufacturers and distributors of dietary supplements and dietary ingredients from marketing products that are adulterated or misbranded. This means that these firms are responsible for evaluating the safety and labeling of their products before marketing to ensure that they meet all the requirements of the law and FDA regulations, including, but not limited to the following labeling requirements: (1) identifying the supplement; (2) nutrition labeling; (3) ingredient labeling; (4) claims; and, (5) daily use information.

The FDA has not approved cannabis as a safe and effective drug for any indication. As of the date of this filing, we have not, and do not intend to file an IND with the FDA, concerning any of our cannabis products.

The FDA has concluded that cannabis is excluded from the dietary supplement definition under sections 201(ff)(3)(B)(i) and (ii) of the U.S. Food, Drug & Cosmetic Act, respectively. The FDA’s position is that because cannabis is a Schedule 1 drug under the CSA, and therefore are illegal drugs that are under the purview of the DEA and DOJ who are charged with enforcing CSA. However, at some indeterminate future time, the FDA may choose to change its position concerning cannabis and may choose to enact regulations that are applicable to cannabis products as either drugs or supplements. In this event, our cannabis products may be subject to regulation.

In addition to strict compliance with all applicable California cannabis related laws and regulations, the Company’s activities intend to comply with the parameters of a recent 9th Cir. Federal Appellate Court decision, United States v. McIntosh, 2016 DJDAR 8484 (Aug. 16, 2016), which held: “the U.S. Department of Justice cannot spend money to prosecute federal marijuana cases if the defendants comply with state guidelines that permit the drug's sale for medical purposes”. The Court reasoned that “if the DOJ punishes individuals for engaging in activities permitted under state law (such as the use, cultivation, distribution and possession of medical marijuana), then the DOJ is preventing state law from being implemented as a practical matter.” “By officially permitting certain conduct, state law provides for non-prosecution of individuals who engage in such conduct. If the federal government prosecutes such individuals, it has prevented the state from giving practical effect to its law providing for non-prosecution of individuals who engage in the permitted conduct." This ruling is consistent with Congress’s “Rohrabacher-Blumenauer” amendment, discussed above, which prohibits the DOJ from using federal funds to prevent certain states “from implementing their own State laws that authorize the use, distribution, possession or cultivation of medical marijuana.”

State Regulation

The State of California requires companies engaged in the cannabis operations to be licensed by the State of California. The Company is regulated by multiple agencies in California:

	·	The Bureau of Cannabis Control (Bureau) is the lead agency in regulating commercial cannabis licenses for medical and adult-use cannabis in California. The Bureau is responsible for licensing retailers, distributors, testing labs, microbusinesses, and temporary cannabis events.

	·	CalCannabis Cultivation Licensing, a division of the California Department of Food and Agriculture (CDFA), ensures public safety and environmental protection by licensing and regulating commercial cannabis cultivators in California.

	·	Manufactured Cannabis Safety Branch, a division of the California Department of Public Health, (CDPH). MCSB is responsible for regulation of all commercial cannabis manufacturing in California. MCSB strives to protect public health and safety by ensuring commercial cannabis manufacturers operate safe, sanitary workplaces and follow good manufacturing practices to produce products that are free of contaminants, meet product guidelines and are properly packaged and labeled.

~~These~~22 3Table ~~divisions require the Company to licensing packages and be compliant with all local, state and environmental regulations. The Company estimates that the cost~~ of licensing each year will be approximately $50,000 - $100,000 per year. The amount will vary year to year depending on what changes have been made to regulations and if any upgrades would be required to be made on the property.Contents

~~The~~These 3 divisions require the Company ~~currently~~(via isVBF) ~~licensed~~to bymaintain its licensing packages and be compliant with all local, state and environmental regulations. The Company estimates that the ~~State~~cost of ~~California~~licensing ~~for~~each ~~the~~year ~~following~~will ~~activities:~~be approximately $50,000 - $100,000 per year. The amount may vary year to year depending on what changes, if any, are made to applicable regulations and if any upgrades are required to be made on the property.

License Type		License Number
Cannabis Cultivation		PAL18-0000119(Provisional)
Cannabis Cultivation Nursery		TAL18-0008563
Medical Use Manufacturing License		CDPH-T00000243
Adult Use Manufacturing License		CDPH-T00000244
Adult Use and Medicinal Distribution		C11-18-0000257-Temp

The Company (via VBF) currently is licensed by the State of California for the following activities:

~~The~~Adult ~~Company~~Use ~~grows~~and ~~its~~Medicinal ~~own~~Distributor ~~cannabis plants through its Cannabis Cultivation~~ License. The material grown and harvested from its cultivation operations are either packaged and sold through the Company’s Distribution license or processed through its Manufacturing license which is later sold through its Distribution license. This allows the Company to sell its own manufactured or other products with a reduced cost to produce since it grew its own raw materials.Provisional

OnValid ~~January~~5-17-19 ~~29,~~to ~~2018, the Company received its Distributor licenses from the State of California for Adult Use and Medicinal Use.~~5-16-20

OnLic# ~~April 11, 2019, VBF Brands received its Annual Manufacturing License from the State of California. The Company also received its Provisional Cannabis Cultivation License.~~C11-0000102-LIC

Provisional Cannabis Cultivation License (Nursery)

Valid 8-7-19 to 8-7-20

Lic # PAL18-0003152

Provisional Cannabis Cultivation License (Adult Use Small Mixed Light Tier2)

Valid 3/15/19- to 3/15/20

Lic# PAL18-0000119

Annual Manufacturing License

Adult and Medicinal Cannabis Products-Provisional

Type 6 Non Volatile Solvent Extraction

Valid 4-11-29 to 4-11-20

Lic# CDPH-10002395

The Company (via VBF) grows its own cannabis plants through its Cannabis Cultivation License. The material grown and harvested from its cultivation operations are either packaged and sold through the Company’s Distribution license (via VBF) or processed through its Manufacturing license (via VBF) which is later sold through its Distribution license (via VBF). This allows the Company (by and through VBF) to sell products it manufactures (at reduced cost since the raw materials are self-grown), as well as products manufactured by third parties.

On January 29, 2018, the Company (via VBF) received its Distributor licenses from the State of California for Adult Use and Medicinal Use.

On April 11, 2019, VBF received its Annual Manufacturing License from the State of California. VBF also received its Provisional Cannabis Cultivation License.

Results of Operations

We have not earned any operational revenues from our inception on September 29, 2016 ~~(inception)~~ through ~~January~~April 3130, 2018.

17Three ~~Table~~Months ofEnded ~~Contents~~April 30, 2018 Compared to Three Months Ended April 30, 2017

Three Months Ended January 31, 2018 Compared to Three Months Ended January 31, 2017

	Three Months Ended
	April 30,
Statement of Operations Data:	2018		2017		Changes

Revenue	$	-	$	-	$	-
Operating expenses		463,939		113,422		350,517
Other expenses		383,079		-		383,079
Net loss	$	847,018	$	113,422	$	733,596

	Three Months Ended
	January 31,
Statement of Operations Data:	2018		2017		Changes
Revenue	$	-	$	-	$	-
Operating expenses		315,783		980		314,803
Other expenses		14,415		-		14,415
Net loss	$	330,198	$	980	$	329,218

Table of Contents

Our interim condensed consolidated financial statements report a net loss of $~~330~~847,~~198~~018 for the three months ended ~~January~~April 3130, 2018 compared to a net loss of $~~980~~113,422 for the three months ended ~~January~~April 3130, 2017. Our losses have increased by $~~329~~733,~~218~~596, primarily as a result of an increase in labor, supplies and greenhouse lease related to the cultivation of medical cannabis with the operations commenced in March 2017, an increase in general and administration expenses and an increase in other expenses related to amortization of debt discount and interest expense from convertible notes.

Six Months Ended April 30, 2018 Compared to Six Months Ended April 30, 2017

	Six Months Ended
	April 30,
Statement of Operations Data:	2018		2017		Changes

Revenue	$	-	$	-	$	-
Operating expenses		779,722		114,402		665,320
Other expenses		397,494		-		397,494
Net loss	$	1,177,216	$	114,402	$	1,062,814

Our interim condensed consolidated financial statements report a net loss of $1,177,216 for the six months ended April 30, 2018 compared to a net loss of $114,402 for the six months ended April 30, 2017. Our losses have increased by $1,062,814, primarily as a result of an increase in labor, supplies and greenhouse lease related to the cultivation of medical cannabis with the operations commenced in March 2017, an increase in general and administration expenses and an increase in other expenses related to amortization of debt discount and interest expense from convertible notes.

Liquidity and Capital Resources

Working Capital

	January 31,			October 31,
	As of			As of
Balance Sheet Data:	2018			2017			Changes
	April 30,			October 31,
Cash and cash equivalents	$	2,740		$	24,656		$	(21,916	)
	2018			2017			Changes
Total current assets	$	2,740		$	24,656		$	(21,916	)
Cash and cash equivalents	$	289,050		$	24,656		$	264,394
Total current liabilities	$	361,728		$	74,731		$	286,997
Total current assets	$	289,050		$	24,656		$	264,394
Working capital (deficiency)	$	(358,988	)	$	(50,075	)	$	(308,913	)
Total current liabilities	$	1,515,735		$	74,731		$	1,441,004
Working capital (deficiency)	$	(1,226,685	)	$	(50,075	)	$	(1,176,610	)

Cash Flows

	Three Months Ended
	Six Months Ended
	January 31,
	April 30,
Cash Flow Data:	2018			2017			Changes
	2018			2017			Changes
Cash Flows used in Operating Activities	$	(~~325~~789,~~957~~746	)	$	(~~980~~121,294	)	$	(~~324~~668,~~977~~452	)
Cash Flows provided by Financing Activities		~~304~~1,~~041~~054,140			10123,200			~~304~~930,~~031~~940
Net Change in Cash During Period	$	~~(21~~264,~~916~~394	)	$	~~(970~~1,906	)	$	~~(20~~262,~~946~~488	)

~~Our total current assets as of January 31, 2018 were $2,740 as compared to total current assets of $~~24~~,656~~ asTable of ~~October 31, 2017. The decrease was primarily due to a use of cash for operating activities.~~Contents

Our total current ~~liabilities~~assets as of ~~January~~April 3130, 2018 were $~~361~~289,~~728~~050 as compared to ~~total~~ current ~~liabilities~~assets of $7424,~~731~~656 as of October 31, 2017. The increase was primarily due to an increase incash, ~~convertible~~from ~~note~~the ~~and~~issuance of convertible notes ~~payable~~during –the ~~related~~six ~~party~~months ended April 30, 2018.

~~The~~Our ~~report~~total ofcurrent ~~our~~liabilities ~~auditors~~as onof ~~our~~April ~~audited~~30, ~~condensed~~2018 ~~consolidated~~were ~~financial statements for the fiscal year ended October 31~~$1, ~~2017~~515,735 ~~contains a going concern qualification~~ as wecompared ~~have~~to ~~suffered~~total ~~losses~~current ~~since~~liabilities ~~our~~of ~~inception.~~$74,731 Weas ~~have~~of ~~minimal~~October ~~assets~~31, ~~and have achieved no operating revenues since our inception~~2017. WeThe ~~have~~increase ~~been~~was ~~dependent~~primarily ondue ~~sales of equity securities~~ to ~~conduct~~an ~~operations.~~increase ~~Unless~~in ~~and~~convertible ~~until~~notes, werelated ~~commence~~party ~~material~~notes ~~operations~~payable, ~~and~~derivative ~~achieve material revenues~~liabilities, wenote ~~will~~accrued ~~remain~~interest ~~dependent~~and ondividend ~~financings to continue our operations.~~payable

18The ~~Table~~report of ~~Contents~~our auditors on our audited consolidated financial statements for the fiscal year ended October 31, 2017, contains a going concern qualification as we have suffered losses since our inception. We have minimal assets and have achieved no operating revenues since our inception. We have been dependent on sales of equity securities to conduct operations. Unless and until we commence material operations and achieve material revenues, we will remain dependent on financings to continue our operations.

Operating Activities

Net cash used in operating activities during the ~~three~~six months ended ~~January~~April 3130, 2018 was $~~325~~789,~~957~~746, compared to $~~980~~121,294 net cash used in operating activities during the ~~three~~six months period ended ~~January~~April 3130, 2017. The increase in cash used in operating activities was mainly due to an increase in net loss.

Investing Activities

During the ~~three~~six months ended ~~January~~April 3130, 2018 and 2017, our Company did not have any investing activities.

Financing Activities

Cash provided by financing activities during the ~~three~~six months ended ~~January~~April 3130, 2018 was $~~304~~1,~~041~~054,140. asDuring ~~compared~~the tosix ~~$10~~months inended ~~cash~~April ~~provided~~30, by2018, ~~financing~~our ~~activities~~Company ~~during~~received ~~the~~$1,152,250 ~~three~~from ~~months~~convertible ~~ended~~notes ~~January~~offset ~~31,~~by ~~2017. During~~ the ~~three~~use ~~months~~of ~~ended~~the ~~January~~proceeds ~~31,~~from ~~2018,~~a ~~our~~convertible ~~Company~~note ~~received~~to ~~$135,000~~repay ~~from~~another convertible note of $276,356, $99,200 from ~~notes payable –~~ related party notes payable and $6978,~~841~~493 from capital contribution. During the ~~three~~six months ended ~~January~~April 3130, 2017, ~~our~~the Company received $10123,200 from ~~bank~~related ~~overdraft~~party notes payable.

Cash Requirements

We will require additional ~~cash~~capital as we expand our business operations. Initially, to carry out our business plan, we will need to raise additional capital through operations, or the issuance of our equity and/or debt securities. There can be no assurance that we will be able to raise additional capital or, if we are able to raise additional capital, the terms we be ~~acceptable~~favorable to us. Currently we do not have any inventory and therefore we have no product to sell to generate operating revenues.

These conditions indicate a material uncertainty that casts significant doubt about our ability to continue as a going concern. We require additional debt or equity financing to have the necessary funding to continue operations and meet our obligations. We have continued to adopt the going concern basis of accounting in preparing our financial statements.

Future Financings

We anticipate continuing to rely on ~~equity~~ sales of our ~~common~~equity ~~stock~~and/or debt securities in order to continue to fund our business operations. Issuances of additional shares of our capital stock will result in dilution to our existing stockholders. There is no assurance that we will achieve any additional sales of our equity securities or arrange for debt or other financing to fund our planned business activities.

Table of Contents

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a “smaller reporting company”,” we are not required to provide the information required by this Item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

19An ~~Table~~evaluation was conducted under the supervision and with the participation of ~~Contents~~our management of the effectiveness of the design and operation of our disclosure controls and procedures as of April 30, 2018. Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective as of such date to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms as a result of the following material weaknesses:

An evaluation was conducted under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of January 31, 2018. Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective as of such date to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms as a result of the following material weaknesses:

The specific material weakness identified by our management was ineffective controls over certain aspects of the financial reporting process because of a lack of a sufficient complement of personnel with a level of accounting expertise and an adequate supervisory review structure that is commensurate with our financial reporting requirements and inadequate segregation of duties. A "material weakness" is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the company's annual or interim financial statements would not be prevented or detected on a timely basis.

We expect to be materially dependent upon a third party to provide us with accounting consulting services for the foreseeable future. Until such time as we have a chief financial officer with the requisite expertise in U.S. GAAP, there are no assurances that the material weaknesses in our disclosure controls and procedures and internal control over financial reporting will not result in errors in our financial statements which could lead to a restatement of those financial statements.

Changes in Internal Controls

There have been no changes in our internal controls over financial reporting identified in connection with the evaluation required by paragraph (d) of Securities Exchange Act Rule 13a-15 or Rule 15d-15 that occurred in the quarter ended ~~January~~April 3130, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

2026 Table of Contents

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

~~From~~The ~~time~~Company’s towholly-owned ~~time~~subsidiary, weVBF ~~may~~Brands, ~~become~~has ~~involved~~had inits ~~litigation~~business ~~relating~~license tosuspended ~~claims~~by ~~arising~~the ~~out~~California ofFranchise ~~its~~Tax ~~operations~~Board in (the ~~normal~~“FTB”). The ~~course~~Company ofand ~~business.~~VBF We are ~~not~~currently ~~involved~~ in ~~any pending legal proceeding or litigation and, to~~ the ~~best~~process of ~~our~~working ~~knowledge,~~with nothe ~~governmental authority is contemplating any proceeding~~ FTB to ~~which~~return weVBF ~~area party or~~ to ~~which~~good ~~any~~standing ofand ~~our~~the ~~properties~~Company isexpects ~~subject,~~VBF ~~which~~to ~~would~~return ~~reasonably~~to begood ~~likely~~standing towith ~~have~~the aFTB ~~material~~in ~~adverse~~the ~~effect~~near ~~on us~~future.

Item 1A. Risk Factors

As a “smaller reporting company”,” we are not required to provide the information required by this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

~~None~~On March 2, 2018, the Company agreed to terms with REI Extracts regarding an extraction and distribution joint venture conducted under the Company’s licenses. To carry out the purposes of the joint venture, REI delivered equipment to SIGO’s facilities to conduct extraction tests. Additionally, REI Extracts also provided consulting services related to cultivation and provided a master grower. The new master grower originally began working with the Company in January 2018. The Company agreed to pay the grower based on the yield of sellable flower per warehouse bay, as follows:

Item 6. Exhibits

Harvested pounds per bay of sellable flower		Incentive Bonus
0-40		$0
40-60		$40 per pound in excess of 40 pounds
60-80		$70 per pound in excess of 40 pounds
80-100		$100 per pound in excess of 40 pounds
100+		$120 per pound in excess of 40 pounds

Exhibit Number		Description
(31)		Rule 13a-14 (d)/15d-14d) Certifications
31.1*		Section 302 Certification by the Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer
(32)		Section 1350 Certifications
32.1*		Section 906 Certification by the Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer
101*		Interactive Data File
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

In December, 2018, SIGO and REI Extracts mutually agreed to terminate their joint venture. All equipment delivered by REI Extracts was removed by REI Extracts and the Company ceased utilizing the master grower provided by REI Extracts.

~~______~~ 27 Table of Contents

*Item ~~Filed herewith~~6. Exhibits

21 Table of Contents

Exhibit Number		Description
(31)		Rule 13a-14 (d)/15d-14d) Certifications
31.1*		Section 302 Certification by the Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer
(32)		Section 1350 Certifications
32.1*		Section 906 Certification by the Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer
101*		Interactive Data File
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

~~SIGNATURES~~____________

In* ~~accordance~~Filed ~~with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized~~herewith.

		SUNSET ISLAND GROUP, INC.
		(Registrant)
Dated: August 16, 2019		/s/ Valerie Baugher
		Valerie Baugher
		President, Chief Executive Officer, Chief Financial Officer and Director
		(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

Table of Contents

22SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		SUNSET ISLAND GROUP, INC.
		(Registrant)

Dated: November 12, 2019		/s/ Valerie Baugher
		Valerie Baugher
		President, Chief Executive Officer, Chief Financial Officer and Director
		(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

Filing Compare · Sunset Island Group